.svg){kind=small}
Inotrem SA, a biotechnology company specializing in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers.The principal objective of this first in-man phase I clinical trial, conducted on a double-blind, randomized, placebo-controlled basis, was to evaluate Motrem’s safety, tolerance and pharmacokinetics.
.avif)
Latest news
Richmond Pharmacology Establishes Expert Regulatory Advisory Board
February 12, 2026
Richmond Pharmacology, a leading clinical research organisation specialising in early-phase and innovative clinical trials
Read moreEvents
Clinical Trials Innovation Programme
10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event
